|
Age (≤50/ >50 years)
|
125(35%)/235(65%)
|
|
Size (≤20/ 21-50/ >50 mm)
|
185(51%)/162(45%)/13(4%)
|
|
Grade (I / II / III)
|
48(13%)/124(34%)/188(52%)
|
|
Involved lymph node (-ve/+ve)
|
206(57%)/154(43%)
|
|
ER status (no/yes)
|
171(47%)/189(53%)
|
|
PR status (no/yes)
|
194(54%)/166(46%)
|
|
HER2 status (no/yes)
|
289(80%)/71(20%)
|
|
Triple-negative tumours (no/yes)
|
240(67%)/120(33%)
|
|
Endocrine therapy (no/yes/unknown)
|
272(76%)/81(22%)/7(2%)
|
|
Chemotherapy (no/yes/unknown)
|
209(58%)/144(40%)/7(2)
|
|
Tumour recurrence (no/local/distant/both)
|
271(75%)/17(5%)/67(19%)/5(1%)
|
|
Alive/cancer death/non cancer death
|
189(53%)/97(27%)/74(21%)
|
